Complete RAPP Stock Valuation Analysis
Comprehensive intrinsic value analysis using 1 different methodologies
RAPP Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 7 peer companies in Healthcare
P/E Ratio
$-14.06
-211.4%
Peer Median: 62.2x
EV/EBITDA
$0.00
-100.0%
Peer Median: 45.4x
P/S Ratio
$0.00
-100.0%
Peer Median: 10.9x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for RAPP's business model and current situation.
Multiple Comparison
| Multiple | RAPP Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -55.9x | 62.2x | 62.2x | -189.8% | Undervalued |
| EV/EBITDA | Infinityx | 45.4x | 45.4x | Infinity% | Overvalued |
| P/S Ratio | Infinityx | 10.9x | 8.3x | Infinity% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.40B | 0.0x | 0.0x | 0.0x | |
| $0.45B | 0.0x | 0.0x | 2.6x | |
| $0.61B | 0.0x | 0.0x | 10.9x | |
| $0.46B | 0.0x | 0.0x | 0.0x | |
| $0.39B | 0.0x | 0.0x | 4.9x | |
| $0.25B | 0.0x | 0.0x | 0.0x | |
| $727.24B | 62.2x | 45.4x | 14.8x |